Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
VIR Quote, Financials, Valuation and Earnings
Last price:
$6.00
Seasonality move
:
40.15%
Day range:
$5.89 - $6.09
52-week range:
$4.16 - $14.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
49.08x
P/B ratio:
1.05x
Volume:
1.2M
Avg. volume:
1.9M
1-year change:
-18.92%
Market cap:
$834.8M
Revenue:
$74.2M
EPS (TTM):
-$3.62
Analysts' Opinion
-
Consensus RatingVir Biotechnology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.22, Vir Biotechnology, Inc. has an estimated upside of 187.04% from its current price of $6.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $6.00.
Fair Value
-
According to the consensus of 6 analysts, Vir Biotechnology, Inc. has 187.04% upside to fair value with a price target of $17.22 per share.
VIR vs. S&P 500
-
Over the past 5 trading days, Vir Biotechnology, Inc. has underperformed the S&P 500 by -0.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vir Biotechnology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vir Biotechnology, Inc. revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Vir Biotechnology, Inc. reported revenues of $240K.
Earnings Growth
-
Vir Biotechnology, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Vir Biotechnology, Inc. reported earnings per share of -$1.17.
Enterprise value:
426.2M
EV / Invested capital:
0.48x
Price / LTM sales:
49.08x
EV / EBIT:
--
EV / Revenue:
25.28x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
-0.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.5M
Return On Assets:
-38.78%
Net Income Margin (TTM):
-2963.54%
Return On Equity:
-48.24%
Return On Invested Capital:
-43.92%
Operating Margin:
-72034.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $118.8M | $78.6M | $16.9M | $2.4M | $240K | |
| Gross Profit | $87.7M | $61.5M | $4.5M | -$566K | -$2.7M | |
| Operating Income | -$673.2M | -$540.9M | -$519.6M | -$216M | -$172.9M | |
| EBITDA | -$647.8M | -$524.8M | -$507.9M | -$213.1M | -$169.9M | |
| Diluted EPS | -$4.49 | -$3.92 | -$3.62 | -$1.56 | -$1.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $2.4B | $1.8B | $1B | $545.7M | |
| Total Assets | $1.2B | $2.7B | $2B | $1.5B | $1B | |
| Current Liabilities | $233.7M | $308.2M | $165.1M | $117.2M | $75.2M | |
| Total Liabilities | $333.9M | $546.1M | $369.8M | $257.6M | $223.4M | |
| Total Equity | $876.3M | $2.1B | $1.7B | $1.2B | $796.1M | |
| Total Debt | $68.6M | $126.9M | $114.1M | $93.4M | $91.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$635.7M | -$466.6M | -$453.5M | -$171.5M | -$167.6M | |
| Cash From Investing | $116.4M | $253.8M | $364.5M | $118.6M | $40.4M | |
| Cash From Financing | $7.7M | $4.8M | $4M | $31K | $102K | |
| Free Cash Flow | -$668.4M | -$473.1M | -$460.4M | -$173.8M | -$167.9M | |
VIR
Sector
Market Cap
$834.8M
$27.8M
Price % of 52-Week High
41.52%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-0.19%
-1.55%
1-Year Price Total Return
-18.92%
-17.47%
Beta (5-Year)
1.346
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.05
200-day SMA
Buy
Level
$5.56
Bollinger Bands (100)
Buy
Level
4.89 - 6.21
Chaikin Money Flow
Sell
Level
-6M
20-day SMA
Sell
Level
$6.30
Relative Strength Index (RSI14)
Sell
Level
47.30
ADX Line
Sell
Level
26.87
Williams %R
Neutral
Level
-79.6992
50-day SMA
Buy
Level
$5.99
MACD (12, 26)
Buy
Level
1.64
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Sell
Level
-9.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0772)
Sell
CA Score
(Annual)
Level (-0.4203)
Buy
Beneish M-Score
(Annual)
Level (-3.805)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.9734)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, VIR has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VIR average analyst price target in the past 3 months is $17.22.
-
Where Will Vir Biotechnology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vir Biotechnology, Inc. share price will rise to $17.22 per share over the next 12 months.
-
What Do Analysts Say About Vir Biotechnology, Inc.?
Analysts are divided on their view about Vir Biotechnology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vir Biotechnology, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Vir Biotechnology, Inc.'s Price Target?
The price target for Vir Biotechnology, Inc. over the next 1-year time period is forecast to be $17.22 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VIR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vir Biotechnology, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VIR?
You can purchase shares of Vir Biotechnology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vir Biotechnology, Inc. shares.
-
What Is The Vir Biotechnology, Inc. Share Price Today?
Vir Biotechnology, Inc. was last trading at $6.00 per share. This represents the most recent stock quote for Vir Biotechnology, Inc.. Yesterday, Vir Biotechnology, Inc. closed at $6.00 per share.
-
How To Buy Vir Biotechnology, Inc. Stock Online?
In order to purchase Vir Biotechnology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VIR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VIR
Sector
P/E ratio
--
23.89x
PEG ratio
-0.11x
-0.01x
P/B ratio
1.05x
1.82x
Price / LTM sales
49.08x
1.60x
Growth Metrics
VIR
Sector
Revenue growth
-89.92%
4.62%
Earnings growth
24.91%
10.88%
Revenue (5-year growth)
55.77%
6.5%
Earnings forecast
-$0.86
-$0.21
Profitability
VIR
Sector
Profitability FY 2024
$58.8M
$3.5M
Return on invested capital
-43.92%
-31.77%
Return on assets
-38.78%
-27.96%
Return on equity
-48.24%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
4
Balance Sheet
VIR
Sector
Total cash
$508.7M
$26.3M
Short term investments
$682.4M
$25.7M
Total assets
$1.4B
$78M
Long term debt
$91.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
